DAY101-102: Pan-RAF Inhibitor DAY101 for Patients with Relapsed/Refractory MAPK-Altered Solid Tumors

Condition: Solid Tumors

Sponsor: Day One Biopharmaceuticals, Inc.

Full Title
DAY101-102: A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination with Other Therapies for Patients with Recurrent, Progressive, or Refractory Solid Tumors and MAPK Pathway Aberrations

Study Treatment
Oral pan-RAF inhibitor DAY101 alone or in combination with oral MEK1/2 inhibitor pimasertib

Eligibility/Info
Advanced or metastatic solid tumor with BRAF fusion, CRAF/RAF1 fusion, or CRAF/RAF1 amplification. Eligible patients will have progressed on/after or not be suitable for any standard of care therapy known to confer clinical benefit in their tumor type.

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.